Leiden, The Netherlands, 9 March 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) financial report for the full year ended 31 December 2016.

Operational highlights
Re-acquisition of all commercial rights to sell RUCONEST® in North America from Valeant in December 2016 in a deal valued at $125 million
Positive results in July 2016 from a Phase II clinical study of RUCONEST® for prophylaxis in patients with HAE, meeting the primary and secondary endpoints
Mr Paul Sekhri took over as Chairman in May 2016 from Mr Jaap Blaak, who remains on the Supervisory Board
In February, extension of distribution agreement with Cytobioteck to include Argentina, Costa Rica, the Dominican Republic and Panama in addition to Colombia and Venezuela
European label change for RUCONEST® in February to remove the need for any pre-exposure testing and to permit use for adolescents with HAE
In July, amendment to distribution agreement with SOBI to enable Pharming to market and sell RUCONEST® directly into an additional 21 countries
Financial highlights
As part of the Valeant transaction, the Company raised €104 million in new funding through a combination of a rights issue, a new senior loan and convertible bonds
Revenues from product sales increased to €13.7 million (2015: €8.6 million) mainly as a result of improved sales in the US
Total revenues increased to €15.9 million (including €2.2 million of license revenue) in 2016 from €10.8 million in 2015 (including €2.2 million in license revenue)
Operating results improved to a loss of €11.5 million from a loss of €12.8 million, in spite of a considerable increase in R&D and commercialization activities
The net result of a loss of €17.5 million increased from a loss of €10.0 million in 2015, mainly as a result of the costs of the financing associated with the Valeant transaction
The equity position improved from €23.8 million in 2015 to €27.5 million in 2016, mainly due to the new financing brought in including a rights issue which raised €8.8 million
Inventories increased from €16.2 million in 2015 to €17.9 million in 2016, largely due to the need to cover the improving sales level in the US and to prepare for the launch of the self-administration kits in Europe
The Company’s cash position increased from €31.8 million at year-end 2015 to €32.1 million at year-end 2016
Post period highlights
EMA amendment to the marketing authorization in Europe to allow self-administration of RUCONEST® for HAE attacks with a new custom-designed RUCONEST® Administration Kit
Conversions by some bondholders in January and February 2017 means that the amount of Amortizing Bonds outstanding is reduced from €45.0 million to €38.9 million. As a result no cash payment was required for the first instalment of the Bonds due on 1 February 2017 and only €125,000 required for the second installment due on 1 March 2017.

lees verder op
https://www.pharming.com/wp-content/uploads/2017/03/PR-Full-Year-Results-2016.pdf

reactie XEA.nl
Winst (opera) in dit jaar, maar hoeveel verliezen staan er NOG op de balans(V&W)? Hoeveel is er weggevallen en niet meer compensabel?

tijd 09.04
Pharming EUR 0,322 +0,009ct vol. 2.594.380 wat een totaal nu al aan omzet.